POEMS syndrome is a rare plasma cell proliferative disorder characterized by polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes. The pathogenesis of POEMS syndrome is still not well understood, but the overproduction of vascular endothelial growth factor (VEGF) probably secreted by plasma cells is thought to be responsible. 1 High-dose melphalan with Auto-SCT has been considered to be an effective strategy, but its treatment-related morbidity should be considered carefully, 2 especially with its poor performance status (PS) owing to polyneuropathy and multiorgan involvement, such as cardiac, respiratory and renal failure. Novel antimyeloma agents have also been recently tried with mixed results. This report presents a severe case of POEMS syndrome, which was successfully treated by combination therapy with bevacizumab (anti-VEGF MoAb) and thalidomide, followed by Auto-SCT.
A 49-year-old male patient had developed subacute progressive sensory-motor polyneuropathy, peripheral edema, gynecomastia, skin hemangioma and skin pigmentation. CT scan revealed hepatosplenomegaly with mild pleural effusion and ascites. A small amount of monoclonal IgA-l protein was detected, and a BM examination revealed 1.6% of plasma cells. An endocrinological examination revealed hypothyroidism and hyperprolactinemia. The patient was diagnosed to have POEMS syndrome in August 2006. He initially received VCR, doxorubicin and dexamethasone and then high-dose CY plus dexamethasone without an objective clinical benefit. He developed severe tetraplegia because of peripheral neuropathy and thereafter became totally bedridden within 4 months from the diagnosis. In December 2006, he transferred to our hospital for Auto-SCT.
At the time of his admission, his serum VEGF was elevated to 1640 pg/ml (normal o680 pg/ml), and nerve conduction studies showed severe axonal loss of both motor and sensory nerve fibers. The patient developed respiratory and cardiac distress because of massive pleural and pericardial effusion and ascites. He was admitted to the intensive care unit and mechanical ventilation was started. Along with intensive care, 5 mg/kg bevacizumab was also administered. Within 2 weeks after bevacizumab administration, the serum VEGF level dramatically decreased to 46 pg/ml, the massive pleural and pericardial effusion and ascites improved rapidly, and the patient recovered from respiratory failure following a tracheotomy. Thalidomide was then started at 100 mg/day. His cardiopulmonary status had improved more significantly with the thalidomide therapy; however, his neurological status remained unchanged, with a Karnofsky PS of 30%. After 4 months' treatment, the serum VEGF level gradually increased again to 4480 pg/ml in May 2007.
PBSCs were collected by mobilization using G Six months after Auto-SCT, the patient was able to walk with a cane and his Karnofsky PS improved to 70%. The serum VEGF level had decreased to 317 pg/ml. On the Medical Research Council scale, his motor strength had improved from 2/5 to 4/5 in the upper extremities and from 1/5 to 4/5 in the lower extremities. Nerve conduction studies showed improvement in amplitudes of compound muscle action potentials in the median and ulnar nerves. BM aspiration revealed 1% of plasma cells. A very small amount of monoclonal IgA-l protein was still detected only by immunofixation.
High-dose chemotherapy supported by Auto-SCT has recently yielded promising results for POEMS syndrome, 3 but its mortality is reported to be considerably higher than those in patients with multiple myeloma. 1 Owing to the high serum VEGF level in POEMS syndrome, bevacizumab has been tried recently with contradictory results. Three cases showed a benefit, including two given with combination chemotherapy, 4,5 whereas two cases showed no improvement. 6, 7 There is also a recently reported case that induced bevacizumab as induction therapy before Auto-SCT. 8 These results suggest that bevacizumab is efficacious for POEMS syndrome, especially when it is used in combination with other chemotherapeutics in the earlier disease stage.
Thalidomide has been recently reported to be effective for POEMS patients. Its neurotoxicity has been thought to interfere with neurological improvement; however, a recent report suggests that the benefit of thalidomide exceeds the risk of its neurotoxicity. 9 In the present case, the patient had poor PS and rapidly developing pleural effusion and ascites, which contraindicated front-line Auto-SCT. Bevacizumab was thought to potentially improve the patient's status by providing a rapid decrease in the serum VEGF level. As expected, bevacizumab induced a dramatic improvement in the serum VEGF level, pleural effusion and ascites, but his neuropathy improvement remained insignificant. Thalidomide was then used to maintain the low VEGF level and induce further clinical improvement without severe hematological toxicity. Thalidomide was partially effective, but the gradually increasing VEGF level suggested that a more intensive strategy was necessary for significant improvement. As the patient was free from any active infection and obvious organ failure in spite of his poor PS, Auto-SCT was performed. Consistent with earlier reports showing that short exposure of thalidomide does not hamper PBSC procurement, it was possible to collect a sufficient number of CD34 þ cells. 10 The patient developed pulmonary distress simultaneously with neutrophil engraftment, which was consistent with an earlier report noting that a high rate of engraftment syndrome in POEMS patients who underwent Auto-SCT could be successfully treatable with corticosteroids. 2 The post-transplant clinical response was dramatic, from 30 to 70% in Karnofsky PS within 6 months, with the serum VEGF level remaining at a low level.
This is the first case report of successful combination induction therapy of bevacizumab and thalidomide, followed by Auto-SCT for POEMS syndrome. This observation is impressive, as it is believed to represent a new treatment option for POEMS patients who were earlier thought to be unable to tolerate Auto-SCT. However, these patients must be selected carefully because of the heterogeneous response of bevacizumab and the high rate of transplant-related complications. Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan E-mail: vzy03227@nifty.com
